08.04.15
Hackensack, N.J.-based BrainStorm Cell Therapeutics Inc., which makes adult stem cell technologies for neurodegenerative diseases, has named Yoram Bibring its new chief financial officer (CFO). Bibring will be responsible for all corporate finance and accounting activities for BrainStorm, and will replace Alla Patlis, the company’s current interim CFO, who will resume her duties as controller of the company.
“We are delighted to have Yoram join the BrainStorm team,” said Tony Fiorino, M.D., Ph.D., BrainStorm’s CEO. “He brings a strong skill set and experience to a company at our stage, with 25 years of leadership in the healthcare and technology industries and a track record of creating shareholder value. We expect him to make an immediate and substantive contribution to BrainStorm.”
“I look forward to being part of a team that shares the vision of developing novel treatments for neurodegenerative diseases such as ALS,” said Bibring. “I am very pleased to join Brainstorm at this exciting time of execution and growth.”
Bibring joins BrainStorm from Sapiens North America, a leading global provider of software solutions for the insurance industry, where he served as the Chief Financial Officer. Prior to Sapiens, he served as the CFO for Silenseed, a clinical stage biopharmaceutical company based in Israel, developing proprietary RNA interference (RNAi) drugs and delivery systems in the oncology space. Before that, he was the CFO for Healthcare Corporation of America, a formerly publicly traded pharmacy-benefit manager. Prior to that, he spent 11 years as CFO for Fundtech, a leading provider of end-to-end financial transaction processing software solutions for financial institutions. In December 2011, Fundtech was sold to GTCR, a private equity firm in a successful all cash deal for approximately $400 million. Bibring also held CFO positions at several other Israeli high-tech companies. Bibring holds a bachelor of science in accounting and economics from Tel Aviv University, and is a certified public accountant.
“We are delighted to have Yoram join the BrainStorm team,” said Tony Fiorino, M.D., Ph.D., BrainStorm’s CEO. “He brings a strong skill set and experience to a company at our stage, with 25 years of leadership in the healthcare and technology industries and a track record of creating shareholder value. We expect him to make an immediate and substantive contribution to BrainStorm.”
“I look forward to being part of a team that shares the vision of developing novel treatments for neurodegenerative diseases such as ALS,” said Bibring. “I am very pleased to join Brainstorm at this exciting time of execution and growth.”
Bibring joins BrainStorm from Sapiens North America, a leading global provider of software solutions for the insurance industry, where he served as the Chief Financial Officer. Prior to Sapiens, he served as the CFO for Silenseed, a clinical stage biopharmaceutical company based in Israel, developing proprietary RNA interference (RNAi) drugs and delivery systems in the oncology space. Before that, he was the CFO for Healthcare Corporation of America, a formerly publicly traded pharmacy-benefit manager. Prior to that, he spent 11 years as CFO for Fundtech, a leading provider of end-to-end financial transaction processing software solutions for financial institutions. In December 2011, Fundtech was sold to GTCR, a private equity firm in a successful all cash deal for approximately $400 million. Bibring also held CFO positions at several other Israeli high-tech companies. Bibring holds a bachelor of science in accounting and economics from Tel Aviv University, and is a certified public accountant.